行情

ALDR

Alder生物制药
ALDR
NASDAQ
已退市
市盈率(FWD)
市销率
市净率
市值
-3.8734
1371.10
7.28
1,579,070,977.92
关于 ALDR
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
展开

ALDR 新闻

更多
美国前外交官:美国外交事务面临严峻挑战
央视 · 1小时前
因存“分类错误”误差 美国五月失业数字比实际好
央视 · 2小时前
美国四任前总统齐发声!呼吁反思国家的“悲剧性失败”
第一财经 · 4小时前
路透:大众汽车正考虑进一步削减成本
界面新闻 · 4小时前
欧佩克将同意延长减产协议至7月末
新浪美股 · 6小时前
瑞幸咖啡遭做空大跌 浑水报告下足血本列5大“罪证”
新浪财经综合 · 7小时前
美5月非农数据出错了?美统计局发言人确认存在“误差”
第一财经 · 10小时前
临近解封日 马来西亚将恢复集市及美容美发行业运营
央视 · 10小时前

热门股票

代码
价格
涨跌幅

微牛提供Alder生物制药(NASDAQ-ALDR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ALDR股票新闻,以帮助您做出投资决策。